Last reviewed · How we verify
CTC-501
CTC-501 is a CD47-SIRPα inhibitor, which works by blocking the interaction between CD47 and SIRPα on the surface of immune cells, thereby enhancing the immune system's ability to recognize and destroy cancer cells.
CTC-501 is a CD47-SIRPα inhibitor, which works by blocking the interaction between CD47 and SIRPα on the surface of immune cells, thereby enhancing the immune system's ability to recognize and destroy cancer cells. Used for Relapsed or refractory acute myeloid leukemia (AML).
At a glance
| Generic name | CTC-501 |
|---|---|
| Sponsor | Chase Therapeutics Corporation |
| Drug class | CD47-SIRPα inhibitor |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CTC-501 is a monoclonal antibody that targets the CD47-SIRPα axis, a pathway that is often exploited by cancer cells to evade immune detection. By blocking this interaction, CTC-501 aims to restore the immune system's ability to recognize and attack cancer cells. This mechanism is thought to be particularly effective in the treatment of hematologic malignancies.
Approved indications
- Relapsed or refractory acute myeloid leukemia (AML)
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CTC-501 CI brief — competitive landscape report
- CTC-501 updates RSS · CI watch RSS
- Chase Therapeutics Corporation portfolio CI